CD437

视黄醇通路激活剂;激活视黄酸受体(RAR)

产品号 #(选择产品)

产品号 #72722_C

视黄醇通路激活剂;激活视黄酸受体(RAR)

总览

CD437是视黄醇相关分子家族中典型的金刚烷芳香视黄酸类化合物,作为视黄酸受体(RAR)γ的选择性激活剂(RAR α、β和γ的Kd分别为6.5µM、2.5µM和77 nM)。(Bernard et al.; Pérez-Rodríguez et al.)。

重编程
·可加快并增加从转染了 Oct4、Sox2、c-Myc 和 Klf4 的小鼠胚胎成纤维细胞(MEFs)中生成的预诱导多能干(iPS)细胞集落的数量(Wang et al.)。

癌症研究
·诱导多种癌细胞的细胞周期阻滞和凋亡(Fontana and Rishi; Jin et al.; Li et al.; Valli et al.)
·降低人头颈鳞状细胞癌细胞系UMSCC22B中鳞状分化标志物——细胞角蛋白1( cytokeratin 1)、involucrin和SPR1的mRNA表达(Sun et al.)。

细胞类型
癌细胞及细胞系,多能干细胞
 
种属
人,小鼠,非人灵长类,其它细胞系,大鼠
 
应用
重编程
 
研究领域
癌症,干细胞生物学
 
CAS 编号
125316-60-1
 
化学式
C₂₇H₂₆O₃
 
纯度
≥ 95 %
 
通路
视黄醇类
 
靶点
RAR
 

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
CD437
Catalog #
72724, 72722
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
CD437
Catalog #
72724, 72722
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (3)

Publications (8)

Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1. Wang W et al. Proceedings of the National Academy of Sciences of the United States of America 2011 NOV

Abstract

Somatic cells can be reprogrammed to induced pluripotent stem cells (iPSCs) by expressing four transcription factors: Oct4, Sox2, Klf4, and c-Myc. Here we report that enhancing RA signaling by expressing RA receptors (RARs) or by RA agonists profoundly promoted reprogramming, but inhibiting it using a RAR-α dominant-negative form completely blocked it. Coexpressing Rarg (RAR-γ) and Lrh-1 (liver receptor homologue 1; Nr5a2) with the four factors greatly accelerated reprogramming so that reprogramming of mouse embryonic fibroblast cells to ground-state iPSCs requires only 4 d induction of these six factors. The six-factor combination readily reprogrammed primary human neonatal and adult fibroblast cells to exogenous factor-independent iPSCs, which resembled ground-state mouse ES cells in growth properties, gene expression, and signaling dependency. Our findings demonstrate that signaling through RARs has critical roles in molecular reprogramming and that the synergistic interaction between Rarg and Lrh1 directs reprogramming toward ground-state pluripotency. The human iPSCs described here should facilitate functional analysis of the human genome.
Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles. Pé et al. European journal of medicinal chemistry 2009 JUN

Abstract

Retinoid-related molecules with an adamantyl group (adamantyl arotinoids) have been described with selective activities towards the retinoid receptors as agonists for NR1B2 and NR1B3 (RARbeta,gamma) (CD437, MX3350-1) or RAR antagonists (MX781) that induce growth arrest and apoptosis in cancer cells. Since these molecules induce apoptosis independently of RAR transactivation, we set up to synthesize novel analogs with impaired RAR binding. Here we describe adamantyl arotinoids with 2,2'-disubstituted biaryl rings prepared using the Suzuki coupling of the corresponding fragments. Those with cinnamic and naphthoic acid end groups showed significant antiproliferative activity in several cancer cell lines, and this effect correlated with the induction of apoptosis as measured by caspase activity. Strikingly, some of these compounds, whereas devoid of RAR binding capacity, were able to activate RXR.
Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity. Valli C et al. Molecular cancer therapeutics 2008 SEP

Abstract

Retinoid-related molecules (RRM) are novel agents with tumor-selective cytotoxic/antiproliferative activity, a different mechanism of action from classic retinoids and no cross-resistance with other chemotherapeutics. ST1926 and CD437 are prototypic RRMs, with the former currently undergoing phase I clinical trials. We show here that ST1926, CD437, and active congeners cause DNA damage. Cellular and subcellular COMET assays, H2AX phosphorylation (gamma-H2AX), and scoring of chromosome aberrations indicate that active RRMs produce DNA double-strand breaks (DSB) and chromosomal lesions in NB4, an acute myeloid leukemia (AML) cell line characterized by high sensitivity to RRMs. There is a direct quantitative correlation between the levels of DSBs and the cytotoxic/antiproliferative effects induced by RRMs. NB4.437r blasts, which are selectively resistant to RRMs, do not show any sign of DNA damage after treatment with ST1926, CD437, and analogues. DNA damage is the major mechanism underlying the antileukemic activity of RRMs in NB4 and other AML cell lines. In accordance with the S-phase specificity of the cytotoxic and antiproliferative responses of AML cells to RRMs, increases in DSBs are maximal during the S phase of the cell cycle. Induction of DSBs precedes inhibition of DNA replication and is associated with rapid activation of ataxia telangectasia mutated, ataxia telangectasia RAD3-related, and DNA-dependent protein kinases with subsequent stimulation of the p38 mitogen-activated protein kinase. Inhibition of ataxia telangectasia mutated and DNA-dependent protein kinases reduces phosphorylation of H2AX. Cells defective for homologous recombination are particularly sensitive to ST1926, indicating that this process is important for the protection of cells from the RRM-dependent DNA damage and cytotoxicity.

更多信息

更多信息
Species Human, Mouse, Non-Human Primate, Other, Rat
Cas Number 125316-60-1
Chemical Formula C₂₇H₂₆O₃
Purity ≥ 95%
Target RAR
Pathway Retinoid
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。